International Psoriasis Council

Advancing Knowledge. Improving Care.

Yuling Shi headshot

Yuling

Shi

,

MD, PhD

Vice President of Shanghai Skin Disease Hospital; Director of the Insitute of Psoriasis, Tongji University School of Medicine
Shanghai Skin Disease Hospital, Tongji University School of Medicine
Shanghai
,
China
Councilor Since: March 17, 2023
IPC Councilor
Dr. Yuling Shi is a professor of dermatology, the Vice President of Shanghai Skin Disease Hospital at the Tongji University School of Medicine, and the founder and director of the Institute of Psoriasis at Tongji University School of Medicine, the first psoriasis institute in China. Dr. Shi has previously pursued postdoctoral training as a Fellow at the Henry Ford Hospital Immunology and Dermatology Research program. She is the General Secretary of the Chinese Dermatologist Association and the Vice President of the Committee on Psoriasis, Chinese Society of Dermatology. Dr. Shi has received numerous honors and titles, including the National High-Level Talent Program, National Model Worker for Women’s Achievements, Special Government Allowance from the State Council, and the National Woman Pacesetter. She has led several research initiatives and programs supported by the National Natural Science Foundation of China (NSFC) and other national organizations, including a State Key Program of the NSFC. Her work includes investigating the skin inflammatory microenvironment in psoriasis.

Additionally, Dr. Shi explored the appropriate use of systematic therapies for psoriasis in Asian populations. Over the past decade, she has published more than 100 peer-reviewed articles in renowned journals, most focusing on psoriasis, skin autoimmunity, and inflammatory skin diseases. Dr. Shi has made significant contributions to advancing the understanding of psoriasis pathogenesis and treatment strategies.
Last Updated:
12/19/2024

Areas of Interest

Studying and optimizing the treatment strategies for psoriasis, such as investigating the best incremental dose regimen of narrow-band ultraviolet B for treating Chinese psoriasis patients; cellular and molecular mechanism of the development and relapse of psoriasis

IPC Committees / Groups

Asia-Pacific Region Steering Committee

Languages Spoken

English, Mandarin

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026